Biomarkers of response to therapy remain to be found, similar to non-sRCC, where PD-L1 expression [54], tumor mutational burden [38], or gene expression profiles [55] have yet to prove their clinical utility to accurately stratify patients. This evidence concerns the gene CD274 and neoplasm.